Peregrine Provides Clarification on NASDAQ Trading Halt

Peregrine's Transfer Agent and DTC Reconcile Shares Held in Trust by DTC

Peregrine Researchers Receive $1.68 Million NIAID Biodefense Grant For Research Into The Treatment Of Lassa Fever

Avid Bioservices Signs Manufacturing Supply Agreement For Production Of Monoclonal Antibodies

Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At The American Association For Cancer Research Meeting

Peregrine's Anti-Angiogenesis 2C3 Anti-VEGF Antibody Presented at American Association For Cancer Research Meeting

Peregrine Reports Voting Results Of Annual Meeting

Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At Angiogenesis Conference

Targeted Delivery of Tissue Factor Research Published in 'Cancer Research'

Peregrine Researchers Receive Grant From Phillip Morris For Lung Cancer Research